Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1628-1645

  Janjan, Nora A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM NITRATE; MEDRONATE TECHNETIUM TC 99M; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89;

BONE MARROW TOXICITY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; SPINAL CORD COMPRESSION;

EID: 0030750510     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1628::aid-cncr13>3.0.co;2-1     Document Type: Conference Paper

References (97)

1. Peteet J, Tay V, Cohen G, MacIntyre J. Pain characteristics and treatment in an outpatient cancer population. Cancer 1986;57:1259-65.
2. Dorrepaal KL, Aaronson NK, van Dam FSAM. Pain experience and pain management among hospitalized cancer patients. Cancer 1989;63:593-8.
3. Brescia FJ, Adler D, Gray G, Ryan MA, Cimino J, et al. Hospitalized advanced cancer patients: a profile. J Pain Sympt Manag 1990;5:221-7.
4. Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991;45:45-8.
5. Mercadante S. Prevalence, causes and mechanisms of pain in home-care patients with advanced cancer. Pain Clin 1994;7:131-6.
6. Greenwald HP, Bonica JJ, Bergner M. The prevalence of pain in four cancers. Cancer 1987;60:2563-9.
7. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone 1991;12(Suppl 1)S9-10.
8. Nielsen OS, Munro AJ, Tannock IF. Bone metastasis: pathophysiology and management policy. J Clin Oncol 1991; 9:509-24.
9. Oda MAS, Schurman DJ. Monitoring of pathological fracture. In: Stoll BA, Parbhoo S, editors. Bone metastases: monitoring and treatment. New York: Raven Press, 1983:271-88.
10. Paterson AHG. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987;8(Supp 1):17-22.
11. Albright JA, Gillespie TE, Butaud TR. Treatment of bone metastases. Semin Oncol 1980;7:418-33.
12. Bunting RW, Boublik M, Blevins FT, Dame CC, Ford LA, Lavine LS. Functional outcome of pathologic fracture secondary to malignant disease in a rehabilitation hospital. Cancer 1992;69:98-102.
13. Ford HT, Yarnold JR. Radiation therapy-pain relief and recalcification. In: Stoll BA, Parbhoo S, editors. Bone metastases: monitoring and treatment. New York: Raven Press, 1983: 343-54.
14. Townsend PW, Smalley SR, Cozad SC, Rosenthal HG, Hassanein RES. Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. Int J Radiat Oncol Biol Phys 1995;31:43-9.
15. Heisterberg L, Johansen TS. Treatment of pathologic fractures. Acta Orthop Scand 1979;50:787-90.
16. Yazawa Y, Frassica FJ, Chao EYS, Pritchard DJ, Sim FH, Shives TC. Metastatic bone disease. Clin Orthop 1990; 251:213-9.
17. Fidler M. Incidence of fracture through metastasis in long bones. Acta Orthop Scand 1981;52:623-7.
18. Weikert DR, Schwartz HS. Intramedullary nailing for impending pathological subtrochanteric fractures. J Bone Joint Surg 1991;73B:668-70.
19. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58: 2589-93.
20. Wood BC. Hormone treatments in the common hormone-dependent carcinomas. Palliat Med 1993;7:257-72.
21. Hortobagyi GN, Libshitz HI, Seabold JE. Osseous metastases of breast cancer-clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 1984;53:577-82.
22. Hoy AM. Radiotherapy, chemotherapy and hormone therapy: treatment for pain. In: Wall PD, and Melzack R, editors. Textbook of pain. Edinburgh: Churchill-Livingstone, 1989: 966-78.
23. Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992;23:217-21.
24. Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J. Bone metastases consensus statement: Int J Radiat Oncol Biol Phys 1992;23:215-6.
25. Arcangeli G, Micheli A, Arcangeli F, Giannarelli D, Pasta O, Tollis A, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989;14:95-101.
26. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic ossesous metastases-final results of the study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
27. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985;55:1468-72.
28. Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys 1983;9:1775-9.
29. Cole DJ. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol (R Coll Radiol) 1989; 1:59-62.
30. Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992;23:74-8.
31. Barak F, Werner A, Walach N, Horn Y. The palliative efficacy of a single high dose of radiation in treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1987; 13:1233-5.
32. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol 1993;20:22-6.
33. Mertens WC. Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy. Semin Oncol 1993;20:49-55.
34. Maxon HR, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC, et al. Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166:501-7.
35. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-81.
36. Breen SL, Powe JE, Porter AT. Dose estimation in Strontium 89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992;33:1316-23.
37. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized Phase III trial to evaluate the efficacy of Strontium 89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
38. Kloiber R, Molnar CP, Barnes M. Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic followup. Radiology 1987;163:719-23.
39. Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA. Clinical experience with Strontium 89 in prostatic and breast cancer patients. Semin Oncol 1993;20:44-8.
40. Porter AT, McEwan AJB. Strontium 89 as an adjuvant to external beam radiation improves pain relief and delays in disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol 1993;20:38-43.
41. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan JB, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64:816-22.
42. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, et al. and Members of the UK Metastron Investigators' Group. Strontium 89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. Semin Oncol 1993;20:32-3.
43. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of treatment with Strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconj Radiopharm 1990;3:91-8.
44. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995;274:420-4.
45. Porter AT, Ben-Josef E. Strontium 89 in the treatment of bony metastases. In: DeVita VT, Hellman S, Rosenberg, SA, editors. Important advances in oncology 1995. Philadelphia: J.B. Lippincott Co., 1995:87-94.
46. Barton M. Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys 1995;31:371-8.
47. Geara FB, Peters LJ, Ang KK, Wike JL, Simon FS, Guttenberger R, et al. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high and low dose rate irradiation. Cancer Res 1992;52:6348-52.
48. Geara FB, Peters LJ, Ang KK, Wike JL, Brock WA. Radiosensitivity measurement of keratinocytes and fibroblasts from radiotherapy patients. Int J Radiat Oncol Biol Phys 1992; 24:287-93.
49. Withers HR, Peters LJ. Biologic aspects of radiation therapy. In: Fletcher GH, editor. Textbook of radiotherapy. Philadelphia: Lea and Febinger, 1980:103-80.
50. Withers HR. Predicting late normal tissue responses. Int J Radiat Oncol Biol Phys 1986;12:693-8. Int J Radiat Oncol Biol Phys 1988;14:649-58.
51. Withers HR. Predicting late normal tissue responses. Int J Radiat Oncol Biol Phys 1986;12:693-8. Int J Radiat Oncol Biol Phys 1988;14:649-58.
52. Peters LJ. Biology of modern radiotherapy for head and neck cancer. Head Neck Cancer 1985;1:37-47.
53. Thames HD, Bentzen SM, Turesson I, Overgaard M, van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 1990;19:219-23.
54. Parsons JT. The effect of radiation on normal tissues of the head and neck. In: Million RR, Cassisi NJ, editors. Management of head and neck cancer: a multidisciplinary approach. Philadelphia: J. B. Lippincott Co, 1984:173-7.
55. Niewald M, Tkocz HJ, Abel U, Scheib T, Walter K, Nieder C, et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases, Int J Radiat Oncol Biol Phys 1996;36:1085-9.
56. Price P, Hoskin PJ, Easton D, Austin A, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bone metastases. Radiother Oncol 1986;6:247-55.
57. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
58. Mithal NP, Needham PR, Hoskin PJ. Retreatment with radiotherapy for painful bone metastases, Int J Radiat Oncol Biol Phys 1994;29:1011-4.
59. Grabowski CM, Unger JA, Potish RA. Factors predictive of completion of treatment and survival after palliative radiation therapy. Radiology 1992;184:329-32.
60. Yankelevitz DF, Henschke C, Knapp PH, Nisce L, Yi Y, Cahill P. Effect of radiation therapy on thoracic and lumbar bone marrow: evaluation with MR imaging. AJR Am J Roentgenol 1991;157:87-92.
61. Steiner RM, Mitchell DG, Rao VM, Schweitzer ME. Magnetic resonance imaging of diffuse bone marrow disease. Radiol Clin North Am 1993;31:383-409.
62. Fossa SD, Winderen M. Does decreased skeletal uptake of 99mTc-methylene biphosphonate in irradiated bone indicate the absence of bone metastases? Radiother Oncol 1993;27:63-5.
63. Poulter CA, Cosmatos D, Rubin P, Urtasun R, Cooper JS, Kuske RR, et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992;23:207-14.
64. Salazar OM, Rubin P, Hendrickson FR, Komaki R, Poulter C, Newall J, et al. Single dose half-body irradiation for palliation of multiple bone metastases from solid tumors-final Radiation Therapy Oncology Group Report. Cancer 1986; 58:29-36.
65. Kuban DA, Schellhammer PF, El-Mahdi AM. Hemibody irradiation in advanced prostatic carcinoma. Urol Clin North Am 1991;18(1):131-7.
66. Jones PW, Bogardus CR, Anderson DW. Significance of initial "performance status" in patients receiving halfbody radiation, Int J Radiat Oncol Biol Phys 1984;10:1947-50.
67. Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens, Int J Radiat Oncol Biol Phys 1989; 17:1281-5.
68. Salazar OM, Scarantino CW, Rubin P, Feldstein ML, Keller BE. Total (half-body) systemic irradiation for occult metastases in non-small cell lung cancer-an Eastern Cooperative Oncology Group Pilot Report. Cancer 1980;46:1932-44.
69. Reed RC, Lowery GS, Nordstrom DG. Single high dose-large field irradiation for palliation of advanced malignancies, Int J Radiat Oncol Biol Phys 1988;9:1243-6.
70. Douglas P, Rossier P, Mirimanoff R-O, Coucke PA. Thirdbody irradiation as an effective palliative treatment for painful multiple bone metastases resistant to chemo-or hormonal treatment. Radiother Oncol 1993;28:76-8.
71. Nag S, Shah V. Once-a-week lower hemibody irradiation (HBI) for metastatic cancers, Int J Radiat Oncol Biol Phys 1986;12:1003-5.
72. Andriole GL, Catalona WJ. Hemibody irradiation in advanced prostatic carcinoma. Urol Clin North Am 1991; 18:131-7.
73. Fielding LP, Henson DE. Multiple prognostic factors and outcome analysis in patients with cancer-communication from the American Joint Committee on Cancer. Cancer 1993;71:2426-9.
74. Lai PP, Perez CA, Lockett MA. Prognostic significance of pelvic recurrence and distant metastases in prostate carcinoma following definitive radiotherapy, Int J Radiat Oncol Biol Phys 1992;24:423-30.
75. Yamashita K, Denno K, Ueda T, Komatsubara K, Kotake T, Usami M, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993;71:1297-302.
76. Kant AK, Glover C, Horm J, Schatzkin A, Harris TB. Does cancer survival differ for older patients? Cancer 1992;70: 2734-40.
77. Goethuys H, Baert L, Van Poppel H, Lieskovsky G, Brady LW, Petrovich Z. Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1997;20:40-5.
78. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988;148:1586-91.
79. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Breast cancer with skeletal metastases at initial diagnosis-distinclive clinical characteristics and favorable prognosis. Cancer 1986;58:178-82.
80. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. Am J Med 1986;81:381-6.
81. Grant R, Papadopoulos SM, Greenberg HS. Metastatic epidural spinal cord compression. Neurol Clin 1991;9:825-41.
82. Boogerd W, van der Sande JJ. Diagnosis and treatment of spinal cord compression in malignant disease. Cancer Treat Rev 1993;19:129-50.
83. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med 1992;327:614-9.
84. Algra PR, Heimans JJ, Valk J, Nauta JJ, Lachniet M, Van Kooten B. Do metastases in vertebrae begin in the body or the pedicles?-imaging study in 45 patients. AJR Am J Roentgenol 1992;158:1275-9.
85. Boogerd W, van der Sande JJ, Kroger R. Early diagnosis and treatment of spinal metastases in breast cancer: a prospective study. J Neurol Neurosurg Psychiatry 1992;55:1188-93.
86. Awan AM, Weichselbaum RR. Palliative radiotherapy. Hematol Oncol Clin North Am 1990;4:1169-81.
87. Maranzano E, Latini P, Checcaglini F, Ricci S, Panizza BM, Aristei C, et al. Radiation therapy in metastatic spinal cord compression - a prospective analysis of 105 consecutive patients. Cancer 1991;67:1311-7.
88. Russi EG, Pergolizzi S, Gaeta M, Mesiti M, D'Aquino A, Delia P. Palliative radiotherapy in lumbosacral carcinomatous neuropathy. Radiother Oncol 1993;26:172-3.
89. Kim RY, Smith JW, Spencer SA, Meredith RF, Salter MM. Malignant epidural spinal cord compression associated with a paravertebral mass: its radiotherapeutic outcome on radiosensitivity. Int J Radiat Oncol Biol Phys 1993;27:1079-83.
90. Turner S, Marosszeky B, Timms I, Boyages J. Malignant spinal cord compression: a prospective evaluation. Int J Radiat Oncol Biol Phys 1993;26:141-6.
91. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991;68:2138-41.
92. Lavey RS, Johnstone AK, Taylor JMG, McBride WH. The effect of hyperfractionation on spinal cord response to radiation. Int J Radiat Oncol Biol Phys 1992;24:681-6.
93. Ang KK, Jiang GL, Guttenberger R, Thames HD, Stephens LC, Smith CD, et al. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol 1992;25:287-94.
94. Powers BE, Beck ER, Gillette EL, Gould DH, LeCouter RA. Pathology of radiation injury to the canine spinal cord. Int J Radiat Oncol Biol Phys 1992;23:539-49.
95. Ruifrok ACC, Kleiboer BJ, van der Kogel AJ. Reirradiation tolerance of the immature rat spinal cord. Radiother Oncol 1992;23:249-56.
96. Landmann C, Hunig R, Gratzi O. The role of laminectomy in the combined treatment of metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 1992;24:627-31.
97. Sundaresan N, DiGiacinto GV, Hughes JEO. Neurosurgery in the treatment of cancer pain. Cancer 1989;63:2365-77.